This review combines the data obtained before the beginning of the 1990s with results
published during the last two decades. The predominant form of the IgM molecule is a …

At the present time, there are three radiolabeled antibodies that have been approved by the
US Food and Drug Administration (FDA) for imaging of cancer, a fourth commercially …

Antibodies play a key role in the immune defence against Gram-negative bacteria. After
binding to bacterial surface antigens, IgG and IgM can activate the complement system and …

J chain is associated with pentameric IgM and dimeric IgA via disulfide bonds involving the
penultimate cysteine residue in the secretory tailpiece of the μ or the α heavy chain. We …

Both IgM and IgA exist as polymeric immunoglobulins. IgM is assembled into pentamers with
J chain and hexamers lacking J chain. In contrast, polymeric IgA exists mostly as dimers with …

Mucosal surfaces are protected by polymeric immunoglobulins that are transported across
the epithelium by the polymeric immunoglobulin receptor (pIgR). Only polymeric IgA and IgM …

Human and mouse IgM can be polymerized as a hexamer in addition to a pentamer. Our
previous work with mouse IgM measured activation of guinea pig complement by highly …

A persistent question in the field of antibody imaging and therapy is whether increased
affinity is advantageous for the targeting of tumors. We have addressed this issue by using a …

Complement is involved in the pathogenesis of many diseases, and there is great interest in
developing inhibitors of complement for therapeutic application. CD59 is a natural …

Recombinant soluble complement inhibitors hold promise for the treatment of inflammatory
disease and disease states associated with transplantation. Targeting complement inhibitors …